Verve Therapeutics, Inc.
Verve Therapeutics, Inc. (VERV) Stock Ownership
Institutional vs insider vs public ownership from 13F and float data — top holders, activity, and insider trades below.
SEC 13F · FMP · VERV · as of Jun 30, 2025
Ownership Breakdown
187
Institutional Holders
▼ 8 vs Q1
$819.43M
Total Inst. Value
▲ $449.98M vs Q1
89.31M
Shares Outstanding
freeFloat 73.19%
72.96M
13F Shares Held
▼ 7.84M vs Q1
Institutional ownership = 13F shares ÷ total outstanding. Insider % = 100 − free float. Public % = free float − institution %. Data: FMP /symbol-positions-summary + /shares-float + SEC EDGAR.
Top Institutional Holders
VERV largest shareholders · institutional ownership
Q2 2025 · SEC 13F
Showing top 10 holders
| Holder | Shares | % Owned | Weight | Value | Reported | Change |
|---|---|---|---|---|---|---|
ALPHABET INC. pharmaceutical preparations | 12.17M | 13.70% | 13.70% | $136.65B | Aug 1, 2025 | ▼ 180.6K |
BLACKROCK, INC. pharmaceutical preparations | 7.36M | 8.29% | 8.29% | $82.62B | Aug 12, 2025 | ▼ 521.5K |
PENTWATER CAPITAL MANAGEMENT LP pharmaceutical preparations | 6.72M | 7.57% | 7.57% | $75.47B | Aug 14, 2025 | NEW |
VANGUARD GROUP INC pharmaceutical preparations | 4.19M | 4.72% | 4.72% | $47.07B | Aug 11, 2025 | ▲ 236.8K |
CASDIN CAPITAL, LLC pharmaceutical preparations | 4.10M | 4.61% | 4.61% | $45.99B | Aug 14, 2025 | ▲ 100.0K |
FARALLON CAPITAL MANAGEMENT LLC pharmaceutical preparations | 3.61M | 4.07% | 4.07% | $40.56B | Aug 14, 2025 | ▲ 2.70M |
ALPINE ASSOCIATES MANAGEMENT INC. pharmaceutical preparations | 2.74M | 3.08% | 3.08% | $30.75B | Aug 5, 2025 | NEW |
STATE STREET CORP pharmaceutical preparations | 2.63M | 2.96% | 2.96% | $29.50B | Aug 14, 2025 | ▼ 464.3K |
HUDSON BAY CAPITAL MANAGEMENT LP pharmaceutical preparations | 2.10M | 2.36% | 2.36% | $23.53B | Aug 18, 2025 | NEW |
ARCH VENTURE MANAGEMENT, LLC pharmaceutical preparations | 2.01M | 2.26% | 2.26% | $22.56B | Aug 14, 2025 | — held |
Data from SEC Form 13F filings. Ownership bar normalised to largest holder. Change flags: isNew / isSoldOut / changeInSharesNumber (FMP extract-analytics/holder).
Institutional Activity
Q2 2025 vs prior quarter
Q2 2025
22
Increased
+9.09M shares14
New Positions
first time holders12
Decreased
−6.56M shares0
Sold Out
fully exitedNet shares change (top 50)
+2.52M
+9.09M / −6.56M
Net new holders
+24
14 new / 0 exited
Based on top 50 institutional holders by position size. Fields: isNew, isSoldOut, changeInSharesNumber (FMP extract-analytics/holder, limit=50).
Insider Buying vs Selling
VERV insider trading · insider activity
Source: SEC Form 4
14
Buy transactions
15
Sell transactions
0.93
Buy/Sell ratio
$0M
Total disposed
Recent Insider Transactions
Showing 10 most recent · Common Stock only
| Name · Role | Date | Type | Shares | Price | Value | After Trans. | Filing |
|---|---|---|---|---|---|---|---|
GV 2017 GP, L.L.C. 10 percent owner | Jul 25, 2025 | U-Tender | 1,800,000 | $10.50 | $18.90M | 0 | Form 4 ↗ |
MacLean Michael F director | Jul 25, 2025 | D-Return | 136,139 | $5.02 | $683.4K | 0 | Form 4 ↗ |
MacLean Michael F director | Jul 25, 2025 | D-Return | 42,200 | $5.73 | $241.8K | 0 | Form 4 ↗ |
Yeshwant Krishna
| Jul 25, 2025 | D-Return | 136,139 | $5.02 | $683.4K | 0 | Form 4 ↗ |
Yeshwant Krishna
| Jul 25, 2025 | D-Return | 42,200 | $5.73 | $241.8K | 0 | Form 4 ↗ |
Yeshwant Krishna
| Jul 25, 2025 | U-Tender | 1,800,000 | $10.50 | $18.90M | 0 | Form 4 ↗ |
Dorval Allison Chief Financial Officer | Jul 25, 2025 | D-Return | 75,000 | $6.01 | $450.8K | 0 | Form 4 ↗ |
Dorval Allison Chief Financial Officer | Jul 25, 2025 | U-Tender | 13,280 | $10.50 | $139.4K | 0 | Form 4 ↗ |
Dorval Allison Chief Financial Officer | Jul 25, 2025 | D-Return | 1,875 | — | — | 0 | Form 4 ↗ |
Dorval Allison Chief Financial Officer | Jul 25, 2025 | D-Return | 180,000 | $12.75 | $2.29M | 0 | Form 4 ↗ |
Source: /insider-trading/search (FMP stable). Buy/Sell direction: acquisitionOrDisposition A=Buy, D=Sell. RSU vesting (M-Exempt) excluded from sentiment bar. All data from SEC EDGAR public filings.
About institutional & insider ownership
Verve Therapeutics, Inc. (VERV) is primarily owned by institutional investors, who hold approximately 81.7% of total shares outstanding. Company insiders own approximately 26.81%, while retail and public investors account for the remaining 0.00%.
The largest institutional shareholder of Verve Therapeutics, Inc. is ALPHABET INC., holding approximately 12.17 million shares — equal to 13.70% of outstanding shares — as of June 30, 2025.
A total of 187 institutional investors currently hold VERV stock, with a combined institutional value of approximately $819,427,354 as of the most recent 13F filing period.
Frequently asked questions
VERV ownershipVerve Therapeutics, Inc. (VERV) is primarily owned by institutional investors, who hold approximately 81.7% of shares. The largest shareholder is ALPHABET INC. with a 13.70% stake. Company insiders hold 26.81%. Data sourced from SEC Form 13F as of June 30, 2025.